NO20003721L - Farmasøytisk aktivt morfolinol - Google Patents

Farmasøytisk aktivt morfolinol

Info

Publication number
NO20003721L
NO20003721L NO20003721A NO20003721A NO20003721L NO 20003721 L NO20003721 L NO 20003721L NO 20003721 A NO20003721 A NO 20003721A NO 20003721 A NO20003721 A NO 20003721A NO 20003721 L NO20003721 L NO 20003721L
Authority
NO
Norway
Prior art keywords
morpholinol
pharmaceutically active
solvates
disease
compound
Prior art date
Application number
NO20003721A
Other languages
English (en)
Other versions
NO20003721D0 (no
NO326878B1 (no
Inventor
Phillip Frederick Morgan
David Lee Musso
John Joseph Partidge
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20003721D0 publication Critical patent/NO20003721D0/no
Publication of NO20003721L publication Critical patent/NO20003721L/no
Publication of NO326878B1 publication Critical patent/NO326878B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet forbindelsen (+)-(2S,3S)-2-(3-klorofey)-3,,-tty-2-morfolinol og farmasøytisk akseptable salter og solvater derav, farmasøytiske sammensetninger som inneholder disse, og det er også beskrevet en fremgangsmåte for behandling av depresjon, oppmerksomhetredusert hyperaktivitetsforstyrrelse (ADHD), fedme, migrene, smerte, seksuell feilfunksjon, Parkinson sykdom, Alzheimers sykdom eller avhengighet av kokain eller nikotin-inneholdende (spesielt tobakk) produkter ved anvendelse av en slik forbindelse, salter, solvater eller sammensetninger.
NO20003721A 1998-01-21 2000-07-20 Anvendelse av morfolinol NO326878B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Publications (3)

Publication Number Publication Date
NO20003721D0 NO20003721D0 (no) 2000-07-20
NO20003721L true NO20003721L (no) 2000-09-19
NO326878B1 NO326878B1 (no) 2009-03-09

Family

ID=26312986

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20003721A NO326878B1 (no) 1998-01-21 2000-07-20 Anvendelse av morfolinol
NO20083529A NO20083529L (no) 1998-01-21 2008-08-14 Farmasoytisk aktivt morfolinol

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20083529A NO20083529L (no) 1998-01-21 2008-08-14 Farmasoytisk aktivt morfolinol

Country Status (30)

Country Link
US (2) US6274579B1 (no)
EP (2) EP1047428B1 (no)
JP (1) JP2002501025A (no)
KR (1) KR100568063B1 (no)
CN (2) CN1203858C (no)
AP (1) AP1229A (no)
AT (1) ATE365042T1 (no)
AU (1) AU755536B2 (no)
BR (1) BR9907203A (no)
CA (1) CA2318268A1 (no)
CY (1) CY1106828T1 (no)
DE (1) DE69936335T2 (no)
DK (1) DK1047428T3 (no)
EA (1) EA002410B1 (no)
EE (1) EE04452B1 (no)
ES (1) ES2288012T3 (no)
HR (2) HRP20000494B1 (no)
HU (1) HUP0100900A3 (no)
ID (1) ID26334A (no)
IL (2) IL137346A0 (no)
IS (1) IS2494B (no)
NO (2) NO326878B1 (no)
NZ (3) NZ505809A (no)
PL (1) PL193622B1 (no)
PT (1) PT1047428E (no)
SG (1) SG115489A1 (no)
SK (1) SK10912000A3 (no)
TR (1) TR200002126T2 (no)
WO (1) WO1999037305A1 (no)
YU (1) YU67102A (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
WO1999038503A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmacological uses of optically pure (+)-bupropion
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
AU7750100A (en) * 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
CA2365428C (en) * 2000-12-21 2008-10-21 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
AU2003231788B2 (en) * 2002-05-17 2008-09-11 Duke University Method for treating obesity
US7384941B2 (en) * 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
KR101167579B1 (ko) * 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
JP2007509856A (ja) * 2003-10-27 2007-04-19 スミスクライン ビーチャム コーポレーション （＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール、その塩および溶媒和物を調製するための酵素触媒動的速度論分割方法
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0506829A (pt) 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
MXPA06012685A (es) * 2004-05-03 2007-01-16 Univ Duke Composiciones para afectar la perdida de peso.
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007079470A2 (en) 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CA2758774C (en) 2009-04-15 2015-02-03 Research Triangle Institute Monoamine reuptake inhibitors
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
CA2800219C (en) 2010-05-21 2019-03-12 Research Triangle Institute 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
CA2800220C (en) 2010-05-21 2019-04-30 Research Triangle Institute Phenylmorpholines and analogues thereof
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) * 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
US6274579B1 (en) 2001-08-14
DE69936335T2 (de) 2008-02-28
KR20010034285A (ko) 2001-04-25
NO20003721D0 (no) 2000-07-20
CN1528753A (zh) 2004-09-15
IL137346A0 (en) 2001-07-24
CA2318268A1 (en) 1999-07-29
IS2494B (is) 2009-02-15
NO326878B1 (no) 2009-03-09
DK1047428T3 (da) 2007-10-08
EP1047428B1 (en) 2007-06-20
AU755536B2 (en) 2002-12-12
NZ529316A (en) 2004-05-28
NZ505809A (en) 2002-09-27
NZ520349A (en) 2004-02-27
HUP0100900A2 (hu) 2002-05-29
HRP20000494A2 (en) 2000-12-31
BR9907203A (pt) 2000-10-17
ATE365042T1 (de) 2007-07-15
JP2002501025A (ja) 2002-01-15
EE04452B1 (et) 2005-04-15
EA002410B1 (ru) 2002-04-25
SK10912000A3 (sk) 2001-04-09
WO1999037305A1 (en) 1999-07-29
EP1047428A1 (en) 2000-11-02
NO20083529L (no) 2000-09-19
PL342012A1 (en) 2001-05-07
EE200000438A (et) 2001-12-17
CN1294513A (zh) 2001-05-09
HRP20000494B1 (en) 2009-02-28
KR100568063B1 (ko) 2006-04-07
US6391875B2 (en) 2002-05-21
HRP20051024A2 (hr) 2006-04-30
PL193622B1 (pl) 2007-02-28
ID26334A (id) 2000-12-14
EA200000691A1 (ru) 2001-04-23
DE69936335D1 (de) 2007-08-02
YU67102A (sh) 2004-12-31
EP1047428A4 (en) 2001-12-19
US20020019396A1 (en) 2002-02-14
IS5568A (is) 2000-07-20
ES2288012T3 (es) 2007-12-16
TR200002126T2 (tr) 2000-12-21
SG115489A1 (en) 2005-10-28
IL161942A0 (en) 2005-11-20
PT1047428E (pt) 2007-09-07
HUP0100900A3 (en) 2002-08-28
AP2000001869A0 (en) 2000-09-30
EP1829544A1 (en) 2007-09-05
AP1229A (en) 2003-12-04
AU2328099A (en) 1999-08-09
CY1106828T1 (el) 2012-05-23
CN1255389C (zh) 2006-05-10
CN1203858C (zh) 2005-06-01

Similar Documents

Publication Publication Date Title
NO20083529L (no) Farmasoytisk aktivt morfolinol
MY153718A (en) Formulation of human antibodies for treating tnf-(?) associated disorders
HUP0104258A2 (hu) HMG-CoA reduktáz inhibítort tartalmazó stabil gyógyszerkészítmények
JP2002501025A5 (no)
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
BR0103169A (pt) Composição farmacêutica para o tratamento do distúrbio de hiperatividade de déficit de atenção (adhd)
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
CA2153340A1 (fr) Application du riluzole dans le traitement de la maladie de parkinson et des syndromes parkinsoniens
GB2373726B (en) Pharmaceutical formulations containing zolmitriptan
DE122006000057I2 (de) Proteinhaltige arzneimittel
ATE412407T1 (de) Arzneimittel zubereitung enthaltend 2-amino-2-ä2- (4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
EP1050301A4 (en) Medicinal compositions
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
ATE277907T1 (de) Blutzuckersenkende und lipidsenkende verbindungen
MY117960A (en) A new salt
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
SE9800905D0 (sv) New therapy in glomerulonephritis
NO20062970L (no) 7-[4-(4-klorobenzyloksy)benzensulfonyl]-8-metoksy-3-metyl-2,3,4,5-tetrahydro-1 H-3-benzazepiniummaleat eller tosyslat som antipsykotia
YU46300A (sh) Farmaceutski aktivni morfolinol
HUP0103544A2 (hu) (R)-3-(N,N-diciklobutil amino)-8-fluor-3,4dihidro-2H-1-benzopirán-5karboxamid-hidrogén-(2R,3R)tartarát monohidrátot és paroxelint tartalmazó gyógyszerkészítmény és eljárás az előállítására
SE0102886D0 (sv) New formulation
SE0102888D0 (sv) New formulation
DE69318418D1 (de) Pharmazeutische zusammensetzungen, die 5-ht 1-rezeptoragonisten und absorptionsverstärker enthalten

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees